Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Andrea Cercek, Dr Cathy Eng and Dr John Strickler, moderated by Dr Christopher Lieu. Published February 14, 2024. (Symposium Video Proceedings)
TARGET AUDIENCE
This program is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers.
LEARNING OBJECTIVES
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 2.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.
PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
HOW TO USE THIS CME ACTIVITY
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASCOGI24/CRC/Video/CME.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer
Mayo Clinic Cancer Center
Consultant, Mayo Clinic in Arizona
Chair, ACCRU Research Consortium
Phoenix, Arizona
Consulting Agreements (to Institution): Arcus Biosciences, Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Merck KGaA, Merus BV, Pfizer Inc, Seagen Inc, Servier Pharmaceuticals LLC; Consulting Agreements (to Self): AbbVie Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Caladrius Biosciences, Celularity, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, Exact Sciences Corporation, Exelixis Inc, Foundation Medicine, GSK, Illumina, Janssen Biotech Inc, Kanaph Therapeutics, Natera Inc, Sanofi, Sobi, Stemline Therapeutics Inc, Treos Bio Ltd, Zai Lab; Data and Safety Monitoring Boards/Committees: 1Globe Health Institute, AstraZeneca Pharmaceuticals LP, Eisai Inc, Exelixis Inc, FibroGen Inc, Merck, Suzhou Kintor; Inventions/Patents: WO/2018/183488 licensed to Imugene, WO/2019/055687 licensed to Recursion; Research Funding (to Institution): AbGenomics, Agios Pharmaceuticals Inc, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Atreca, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merus BV, Mirati Therapeutics Inc, Novartis, Pfizer Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc; Scientific Advisory Boards: Artiva Biotherapeutics Inc, Immuneering Corporation, Imugene, Panbela Therapeutics Inc, Replimune, Xilis; Nonrelevant Financial Relationships: MJH Life Sciences, Pancreatic Cancer Action Network, The Valley Hospital, UptoDate.
Andrea Cercek, MD
Section Head, Colorectal Cancer
Co-Director, Center for Young Onset Colorectal and Gastrointestinal Cancers
Associate Attending
Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Advisory Committees: Bayer HealthCare Pharmaceuticals, GSK, Janssen Biotech Inc, Merck, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: GSK, Seagen Inc.
Cathy Eng, MD
Professor of Medicine, Hematology and Oncology
David H Johnson Endowed Chair in Surgical and Medical Oncology
Director for Strategic Relations
Co-Chairman, NCI GI Steering Committee
Co-Director, GI Oncology
Co-Leader, GI Cancer Research Program
Director, Young Adult Cancers Program
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
Consulting Agreements: Amgen Inc, Elevation Oncology, GE Healthcare, GSK, HOOKIPA Pharma Inc, IGM Biosciences Inc, Merck, Natera Inc, Pfizer Inc, Seagen Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Contracted Research (Paid to Vanderbilt): Gritstone bio, Hutchison MediPharma, Janssen Biotech Inc, Merck; Data and Safety Monitoring Board/Committee: Mirati Therapeutics Inc.
John Strickler, MD
Associate Professor
Associate Director, Clinical Research – GI
Duke University
Durham, North Carolina
Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Merck, Natera Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Seagen Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Xilio Therapeutics; Contracted Research: AbbVie Inc, Amgen Inc, AStar D3, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Curegenix, Daiichi Sankyo Inc, Erasca, Genentech, a member of the Roche Group, GSK, Leap Therapeutics Inc, Lilly, Seagen Inc; Data and Safety Monitoring Boards/Committees: BeiGene Ltd, Seagen Inc; Stock Options — Private Company: Triumvira Immunologics.
SURVEY PARTICIPANTS
Kristen K Ciombor, MD, MSCI — Advisory Committee: Bayer HealthCare Pharmaceuticals, Exelixis Inc, Incyte Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Personalis, Pfizer Inc, Replimune, Seagen Inc; Consulting Agreements: Merck, Pfizer Inc; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bristol Myers Squibb, Calithera Biosciences, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Incyte Corporation, Merck, NuCana, Pfizer Inc, Seagen Inc. Arvind Dasari, MD, MS — Advisory Committee: HUTCHMED, Illumina, Personalis, Takeda Pharmaceuticals USA Inc; Contracted Research: Eisai Inc, Enterome, Guardant Health, HUTCHMED, Xencor.
MODERATOR
Christopher Lieu, MD
Associate Professor of Medicine
Associate Director for Clinical Research
Co-Director, GI Medical Oncology
University of Colorado Cancer Center
Aurora, Colorado
No relevant conflicts of interest to disclose.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Bristol Myers Squibb, Natera Inc, and Pfizer Inc.
Release date: February 2024
Expiration date: February 2025
After completing the post-test, learners may download and review the answers here in order to identify further areas of study.
(WIFI is recommended for best performance):